Lacticaseibacillus rhamnosus B6 alleviates metabolic dysfunction-associated fatty liver disease by suppressing intestinal LPS synthesis and regulating lipid metabolism

These findings demonstrate that <i>L. rhamnosus</i> B6 is a promising probiotic for MAFLD alleviation via dual mechanisms of attenuating inflammation and regulating lipid metabolism. This study provides compelling evidence for the specific protective effects of <i>L. rhamnosus</i> B6 against MAFLD and offers a novel probiotic-based therapeutic strategy for MAFLD.